SPOTLIGHT -
Isolated cryptorchidism is linked to a higher likelihood of testicular cancer development, say researchers from the United Kingdom.
Talazoparib plus enzalutamide significantly delays progression in HRR gene–altered mCRPC
The benefit in radiographic progression-free survival extended across all subgroups of patients with HRR-deficient metastatic castration-resistant prostate cancer.
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Cabozantinib plus nivolumab/ipilimumab shows promise in renal cell carcinoma with variant histology
Overall, 86% maintained a response for greater than 6 months.
2023 AUA highlights in benign urology
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Radium-223 yields OS of approximately 18 months in mCRPC
“Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” said Daniel Y. Song, MD.
Talazoparib/enzalutamide combo shows manageable safety profile in mCRPC
A total of 398 patients with mCRPC, unselected for homologous recombination repair gene alterations.were included in the safety cohort.